期刊文献+

氟喹诺酮类药物体外多步诱导人型支原体耐药的研究

Study on the drug resistance of Mycoplasma hominis in vitro multiple step induced by fluoroquinolones
下载PDF
导出
摘要 目的探讨氟喹诺酮类药物体外多步诱导人型支原体耐药的状况,指导临床合理用药。方法将Mh标准株和临床分离敏感株在体外进行四种氟喹诺酮类药物的多步诱导,然后检测其诱导前后对这四种药物的MIC变化。结果所有Mh敏感株经四种药物诱导后对诱导药物和非诱导药物均产生不同程度的耐药和交叉耐药,且这种体外获得性耐药具有较好的稳定性。结论体外长时间、低浓度的氟喹诺酮类药物刺激将诱导Mh产生耐药和交叉耐药,这对临床合理选用抗生素具有重要的指导意义。 Objective To explore the resistance of Mycoplasma hominis to fluoroquinolones in vitro for guiding reasonablly chaical apphcatlon of antibiotics. Methods A Mycoplasma hominis standard strain and two clinical strains were induced stepwise with four kinds of fluoroquinolones, and minimum inhibition concentrations were detected before and after inducement. Results .All Mh sensitive strains became resistant and cross - resistant to four kinds of inducing and non - inducing fluoroquinolones after induced. Conclusion The resistance and crossresistance of Mycoplasma hominis to fluoroquinolones can be induced after In vito long time and lower concentration stimulation with the fluoroquinolones, it helpful for guidance of reasonable choice of antibiotics in clinical practice.
出处 《中国热带医学》 CAS 2007年第6期881-882,共2页 China Tropical Medicine
基金 深圳市科技计划项目(NO200603087)
关键词 人型支原体 氟喹诺酮 耐药性 Mycoplasma hominis (Mh) Fluoroquinolones Drug resistance
  • 相关文献

参考文献8

  • 1吴移谋,余敏君,尹卫国,朱翠明,刘腾飞,曾铁兵,谭立志.从临床标本中定量检测泌尿生殖道支原体耐药性的研究[J].中华医学检验杂志,1998,21(6):335-337. 被引量:99
  • 2Michea-Hamzehpour M,Kahr A,Pechere JC.In vitro stepwise selection of resistance to quinolones,β-lsctams and amikacin in nosocomial Gramnegative bacilli[J].Infection,1994,2:105.
  • 3Bebear CM,Bove JM,Bebear C,et al.Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones[J].Antimicrob Agents Chemother,1997,41 (2):269 ~ 273.
  • 4Bebear CM,Renaudin H,Charron A,et al.Alterations in topoisomerase Ⅳ and DNA gyrase in quinolone-resistant mutants of mycoplasma hominis obtained in vitro[J].Antimicrob Agents Chemother,1998,42 (9):2304 ~2311.
  • 5张冉,吴移谋,向斌,陈丽丽,李庆华.次抑菌浓度的喹诺酮类药物诱导人型支原体耐药与交叉耐药的研究[J].实用预防医学,2000,7(1):12-14. 被引量:1
  • 6Gruson D,Pereyre S,Renaudin H,et al.In vitro development of resistance to six and four fluoroquinolones in mycoplasma pneumoniae and mycoplasma hominis,respectively[J].Antimicrob Agents Chemother,2005,49(3):1190~ 1193.
  • 7叶萍,王晓川,吴志华.人型支原体氟喹诺酮耐药性的分子机制[J].中国麻风皮肤病杂志,2005,21(10):805-807. 被引量:10
  • 8Pereyre S,Renaudin H,Bebear C,et al.In vitro activities of the newer quinolones garenoxacin,gatifloxacin,and gemifloxacin against human mycoplasmas[J].Antimicrob Agents Chemother,2004,48:3165 ~ 3168.

二级参考文献25

  • 1吴移谋,尹卫国,余敏君,刘腾飞,占利生.3种抗菌药物体外抗5种支原体的活性研究[J].中国现代医学杂志,1996,6(1):8-9. 被引量:14
  • 2任冰,国外医学.抗生素分册,1997年,18卷,386页
  • 3吴移谋,中国现代医学杂志,1996年,6期,8页
  • 4吴移谋,中华皮肤科杂志,1994年,27卷,134页
  • 5吴移谋,中华皮肤科杂志,1991年,24卷,251页
  • 6吴移谋,中华医学检验杂志,1991年,14卷,157页
  • 7Bebear CM, Bove JM, Bebear C, et al. Characterization of mycoplasma hominis mutations involved in resistance to fluoroquinolones.Antimicrob Agents Chemother 1997 ;41 : 269 - 273.
  • 8Bebear CM, Renaudin H, Charron A, et al. Alterations in topoisomerase IV and DNA gyrase in quinolone - resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998;42:2304 - 2311.
  • 9Bebear CM, Renaudin J, Charron A, et al. Mutations in the gyrA,parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother 1999;43:954 - 956.
  • 10Bebear CM, Renaudin H, Charron A, et al. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother 2003 ;47 : 3323 - 3325.

共引文献107

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部